Newspaper publication of extract of Consolidated Unaudited Financial Results for the Quarter ended June 30, 2025.
ROSSARI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Rossari Biotech has published the extract of its consolidated unaudited financial results for Q1 FY26 in Financial Express (English) and Loksatta (Marathi), as required under SEBI LODR Regulations. On a consolidated basis, total income from operations rose to Rs. 5,437.16 million from Rs. 4,896.50 million in Q1 FY25 (up ~11% YoY). However, net profit after tax slipped slightly to Rs. 335.96 million from Rs. 348.99 million (down ~3.7% YoY). Basic EPS declined to Rs. 6.07 from Rs. 6.32. On a standalone basis, revenue grew ~21.6% YoY to Rs. 3,657.58 million and profit after tax rose to Rs. 262.33 million from Rs. 243.28 million (up ~7.8% YoY). The results were approved by the board on July 19, 2025 and reviewed by statutory auditors.
Mixed signals for shareholders: revenue growth is healthy, but consolidated profit and EPS saw a slight YoY decline, suggesting margin pressure. The standalone business, however, showed stronger growth in both revenue and profit. The filing itself is a routine regulatory disclosure and unlikely to move the stock on its own.